T lymphocyte-mediated bone marrow failure is a recently recognized clinical disorder, but the T lymphocyte subsets responsible for mediating the inhibitory effect have not been identified. We obtained T lymphocytes from the bone marrow of two patients with T lymphocyte-mediated granulopoietic failure, exposed them to monoclonal antibodies (OKT3, OKT4, and OKT8) in cytotoxicity assays, then recombined the treated T cells with autologous T-depleted marrow cells in clonal assays for granulocyte/macrophage progenitors (CFU-GM). Treatment of T cells with OKT3 and OKT8 abrogated their granulopoietic inhibitory effect but treatment with OKT4 did not. Therefore, in these two patients, the lymphocytes that played a role in the inhibition of granulopoiesis were of the cytotoxic/suppressor subset.
INTRODUCTION
Thymus-dependent lymphocytes and their subsets function as critical components of normal mammalian hematopoiesis. For example, T lymphocytes promote the growth of pluripotent (1-3) and committed (4) (5) (6) (7) (8) hemopoietic progenitor cells and interact with mononuclear phagocytes to regulate granulopoiesis in vitro (8) . In vitro studies in a number of laboratories, including our own (9) (10) (11) (12) , have also provided evidence that a major pathophysiologic abnormality in some patients with bone marrow failure derives from T lymphocytes that inhibit hematopoiesis (9) (10) (11) (12) (13) (14) . While the term "suppressor" has been sometimes used to describe the hemopoietic activity of these T lymphocytes, it is not yet known whether these cells are the same as those more widely recognized (and more thoroughly studied) suppressor T lymphocyte subpopulations that inhibit certain phases of the immune response. To address this concern we have used monoclonal antibodies against the suppressor/cytotoxic and helper/inducer subsets (15, 16) in cytotoxicity assays against T lymphocytes obtained from the bone marrow of two patients with T lymphocyte-mediated granulopoietic failure.
METHODS
Patients. We studied cells from two patients in whom we had previously documented T lymphocyte-mediated hemopoietic failure. The first patient is a 52-yr-old woman with aplastic anemia (10) who had been in complete remission for 2 yr while taking 50 mg azathioprine daily. Progressive neutropenia and thrombocytopenia developed 6 mo after discontinuation of azathioprine. Cells were obtained at that time. A second study was performed 5 mo later during remission.
The second patient is a man with prednisone-responsive T lymphocyte mediated granulopoietic failure and Felty's syndrome (9) . Prednisone had been discontinued for 11 mo before neutropenia (0.4 x 109 neutrophils/ml) recurred at which time cells were obtained. A second study was performed 7 mo later during a second relapse.
Volunteers. Bone marrow cells were obtained from five paid consenting normal adult volunteers and were processed as described below.
Bone marrow cells. Single-cell suspensions of low density marrow cells were prepared as described previously using Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, N. J.) (8) (9) (10) 12) . Phagocyte-depleted low density marrow cells were prepared using an iron magnet technique (9) and T lymphocytes were removed by depleting those phagocytedepleted low density cells that formed sheep erythrocyte rosettes on a second Ficoll-Paque gradient (8) (9) (10) (11) (12) . The T lymphocytes removed were isolated by gentle agitation and osmotic lysis (8, 9, 17 TD+OKT3-T  TD+OKI4-T   TD+OKT&8   P1   64±+15 163+20  41±+11   107±20  20±4  114±20  P2  62±10  110±11  64±10  85±16  2±2  245±39  Vi  162± 10  163±33*  176± 17  192±26  54±21  184±30   V2  80±18*  91±25  77±16  44±7  45±8  V3  202±31  212±32*  200±11  176±17  74±14  166±17  V4  85±10  *  61±10  64±6  112±13  75±4  V5  182±39  160±8   181±+10  162±16 TD, T lymphocyte depleted (E rosette depletion) LDBMC. TD+T, Complement treated T lymphocytes added back to TD. TD+OKT3-T, OKT3 antibody and complement treated T-cells added back to TD. TD+OKT4-T, OKT4 treated T-cells added back to TD. TD+OKT8-T, OKT8 treated T-cells added back to TD. * Depletion of T lymphocytes from LDBMC from 27 normal volunteers has never augmented colony stimulated activity-stimulated granulocyte colony growth.
were treated with 0. Clonal assays (CFU-GM) were performed using methylcellulose (0.9%) in alpha medium with 15% fetal calf serum (8, 11, 12) , and 10% human placental conditioned medium (18) Table I . In patient 1, results of a second study (during another relapse) were similar. In patient 2, a second study (during remission) showed markedly improved colony growth (216±21 colonies per plate) no T-mediated inhibition and no change when T8-(229±+28) or T4-(208±+30) cells were added. Colony-stimulated activity-stimulated colony growth of cells from both patients increased significantly (P < 0.001) when T lymphocytes were removed by E rosette depletion. When untreated (not shown) or complement-treated T lymphocytes (Table I) were added back, suppression was again noted but when OKT3 and OKT8 treated T-cells were added there was no inhibition of colony growth. In fact, in P2 the combination of marrow cells with T8-T lymphocytes yielded colony growth that exceeded that of cells from which T cells had been removed by rosette depletion or by OKT3 antibody (Table I) . Treatment with OKT4 antibody did not abrogate T suppression.
In cell cultures from normal volunteers T removal by OKT3 cytotoxicity or E rosette depletion failed to enhance colony growth. Selective removal of T8+ cells by cytotoxicity failed to enhance colony growth but removal of T4+ cells inhibited colony growth (Table I) .
DISCUSSION
There are interesting parallels between suppressor T-cells of immunity (19, 20) and T cells that inhibit granulopoiesis (9) (10) (11) (12) . For example, in patients with prednisone-responsive hypogammaglobulinemia cortisol-sensitive T lymphocytes account for suppression of B cell function (19, 20) . Similarly, cortisol sensitive T lymphocytes that mediate prednisone-responsive 1598 G. C. Bagby, Jr.
hemopoietic failure have also been described (9-11). Furthermore, both types of "suppressor" T cells produce soluble factors that inhibit target cell function in vitro (9, 10, 19, 20) .
The studies described herein were designed to test the hypothesis that the T lymphocyte subset that inhibits granulopoiesis in patients with T lymphocyte mediated hemopoietic failure possesses some surface antigens in common with T lymphocyte suppressors of immunity. In vitro granulopoiesis in both patients was significantly enhanced by removal of T lymphocytes from the marrow cell suspension, and was inhibited when autologous T lymphocytes were added back (Table I) . T lymphocytes treated with a monoclonal antibodies directed against either a common T cell antigen (OKT3) or against an antigen found on the cytotoxic/suppressor subset (OKT8) failed to inhibit the granulopoietic activity of autologous T-depleted marrow cells (Table I) . Indeed, in one patient colony growth was maximal when T lymphocytes were selectively T8-, which suggests that some T8-cells may have functioned as granulopoietic helpers. None of the above phenomena were noted in studies on cells from normal volunteers or in a study on cells from patient one obtained during azathioprine-induced remission.
A major limitation of cytotoxicity assays is that critical cell-cell interactions may be missed. For 
